Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance

• Published in: Current drug targets Vol. 21; no. 2; p. 167
• Main Authors: Wang, Ling, Wang, Qi, Xu, Yangchun, Cui, Manhua, Han, Liying
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2020
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Benzimidazoles - therapeutic use; BRCA1 Protein - genetics; BRCA1 Protein - metabolism; BRCA2 Protein - genetics; BRCA2 Protein - metabolism; Carcinoma, Ovarian Epithelial - drug therapy; DNA Repair - drug effects; Drug Resistance, Neoplasm - drug effects; Female; Humans; Indazoles - therapeutic use; Indoles - therapeutic use; Neoplasm Recurrence, Local - drug therapy; Ovarian Neoplasms - drug therapy; Phthalazines - therapeutic use; Piperazines - therapeutic use; Piperidines - therapeutic use; Poly(ADP-ribose) Polymerase Inhibitors - adverse effects; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Poly(ADP-ribose) Polymerases - metabolism; toxicity; MeSH; drug resistance mechanism; ovarian cancer; PARP inhibitors; targeted treatment

The standard treatment for advanced ovarian cancer is cytoreductive surgery followed by cytotoxic chemotherapy. However, it has high risk of recurrence and poor prognosis. Poly(ADPribose) polymerase (PARP) inhibitors selectively target DNA double-strand breaks (DSBs) in tumor cells that cannot be re...